We showed recently [10] that this mechanism does not induce proliferation in normal human fetal liver cells positive for CD326, in contrast to tumor cells; moreover, gene knockdown or treatment with an inhibitor of ADAM17 rather increased the number of CD326-positive normal fetal liver cells. This evidence concerns the gene ADAM17 and neoplasm.